Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Carltonine-derived compounds for targeted butyrylcholinesterase inhibition

F. Pidany, J. Kroustkova, J. Jenco, KH. Breiterova, L. Muckova, L. Novakova, J. Kunes, J. Fibigar, T. Kucera, M. Novak, A. Sorf, M. Hrabinova, L. Pulkrabkova, J. Janousek, O. Soukup, D. Jun, J. Korabecny, L. Cahlikova

. 2024 ; 15 (5) : 1601-1625. [pub] 20240322

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012725

The investigation into human butyrylcholinesterase (hBChE) inhibitors as therapeutic agents for Alzheimer's disease (AD) holds significant promise, addressing both symptomatic relief and disease progression. In the pursuit of novel drug candidates with a selective BChE inhibition pattern, we focused on naturally occurring template structures, specifically Amaryllidaceae alkaloids of the carltonine-type. Herein, we explored a series of compounds implementing an innovative chemical scaffold built on the 3- and 4-benzyloxy-benzylamino chemotype. Notably, compounds 28 (hBChE IC50 = 0.171 ± 0.063 μM) and 33 (hBChE IC50 = 0.167 ± 0.018 μM) emerged as top-ranked hBChE inhibitors. In silico simulations elucidated the binding modes of these compounds within hBChE. CNS availability was predicted using the BBB score algorithm, corroborated by in vitro permeability assessments with the most potent derivatives. Compound 33 was also inspected for aqueous solubility, microsomal and plasma stability. Chemoinformatics analysis validated these hBChE inhibitors for oral administration, indicating favorable gastrointestinal absorption in compliance with Lipinski's and Veber's rules. Safety assessments, crucial for the chronic administration typical in AD treatment, were conducted through cytotoxicity testing on human neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cell lines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012725
003      
CZ-PrNML
005      
20240726151329.0
007      
ta
008      
240723s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1039/d4md00060a $2 doi
035    __
$a (PubMed)38784455
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pidany, Filip $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz
245    10
$a Carltonine-derived compounds for targeted butyrylcholinesterase inhibition / $c F. Pidany, J. Kroustkova, J. Jenco, KH. Breiterova, L. Muckova, L. Novakova, J. Kunes, J. Fibigar, T. Kucera, M. Novak, A. Sorf, M. Hrabinova, L. Pulkrabkova, J. Janousek, O. Soukup, D. Jun, J. Korabecny, L. Cahlikova
520    9_
$a The investigation into human butyrylcholinesterase (hBChE) inhibitors as therapeutic agents for Alzheimer's disease (AD) holds significant promise, addressing both symptomatic relief and disease progression. In the pursuit of novel drug candidates with a selective BChE inhibition pattern, we focused on naturally occurring template structures, specifically Amaryllidaceae alkaloids of the carltonine-type. Herein, we explored a series of compounds implementing an innovative chemical scaffold built on the 3- and 4-benzyloxy-benzylamino chemotype. Notably, compounds 28 (hBChE IC50 = 0.171 ± 0.063 μM) and 33 (hBChE IC50 = 0.167 ± 0.018 μM) emerged as top-ranked hBChE inhibitors. In silico simulations elucidated the binding modes of these compounds within hBChE. CNS availability was predicted using the BBB score algorithm, corroborated by in vitro permeability assessments with the most potent derivatives. Compound 33 was also inspected for aqueous solubility, microsomal and plasma stability. Chemoinformatics analysis validated these hBChE inhibitors for oral administration, indicating favorable gastrointestinal absorption in compliance with Lipinski's and Veber's rules. Safety assessments, crucial for the chronic administration typical in AD treatment, were conducted through cytotoxicity testing on human neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cell lines.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kroustkova, Jana $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz
700    1_
$a Jenco, Jaroslav $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz $1 https://orcid.org/0000000186678303
700    1_
$a Breiterova, Katerina Hradiska $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz
700    1_
$a Muckova, Lubica $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Novakova, Lucie $u Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000215558870 $7 xx0062498
700    1_
$a Kunes, Jiri $u Faculty of Pharmacy in Hradec Kralove, Department of Bioorganic and Organic Chemistry, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic
700    1_
$a Fibigar, Jakub $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Kucera, Tomas $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Novak, Martin $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz
700    1_
$a Sorf, Ales $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Hrabinova, Martina $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Pulkrabkova, Lenka $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Janousek, Jiri $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
700    1_
$a Jun, Daniel $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic $1 https://orcid.org/0000000208826304 $7 xx0040498
700    1_
$a Korabecny, Jan $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic $1 https://orcid.org/0000000169777596 $7 xx0119837
700    1_
$a Cahlikova, Lucie $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz $1 https://orcid.org/0000000215558870 $7 xx0062498
773    0_
$w MED00208004 $t RSC medicinal chemistry $x 2632-8682 $g Roč. 15, č. 5 (2024), s. 1601-1625
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38784455 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151321 $b ABA008
999    __
$a ok $b bmc $g 2125457 $s 1224588
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 15 $c 5 $d 1601-1625 $e 20240322 $i 2632-8682 $m RSC medicinal chemistry $n RSC Med Chem $x MED00208004
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...